• Harmony Biosciences Holdings recently announced that six abstracts on narcolepsy and idiopathic hypersomnia, featuring clinical and patient-experience data on pitolisant, were accepted for poster presentation at the SLEEP 2026 APSS meeting in Baltimore.
• This concentration of late-stage data highlights how Harmony is working to deepen the clinical profile of its core sleep-wake franchise at a time when investors are closely watching its broader neurology pipeline.
• We’ll now examine how the upcoming Pitolisant GR regulatory milestone could influence Harmony’s investment narrative and future growth expectations.

This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.

Harmony Biosciences Holdings Investment Narrative Recap

To own Harmony Biosciences, you need to believe that WAKIX and next-generation pitolisant formulations can support a durable sleep-wake franchise while the neurology pipeline broadens future earnings. The new SLEEP 2026 posters deepen clinical understanding of pitolisant but do not materially change the near term focus on the Pitolisant GR New Drug Application (NDA) or the key risk of revenue concentration in WAKIX as patent expiry and competition approach.

The most relevant recent announcement for this news is Harmony’s plan to file a New Drug Application for Pitolisant GR in Q2 2026, positioning an extended-release formulation as a potential follow-on to the current WAKIX franchise. Together with the new SLEEP 2026 data set, this regulatory milestone could become an important test of how effectively Harmony can extend the pitolisant life cycle and partially offset future pressures on WAKIX exclusivity and pricing power.

Yet beneath the headline growth story, the heavy dependence on WAKIX and the timing of generic entry remain issues investors should be aware of...

Harmony Biosciences Holdings' narrative projects $1.2 billion revenue and $333.5 million earnings by 2028.

Uncover how Harmony Biosciences Holdings' forecasts yield a $47.30 fair value, a 34% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already modeling revenue falling about 5.2 percent a year to roughly US$766 million by 2029, so if you worry that WAKIX concentration and future competition could weigh more heavily than consensus assumes, this SLEEP 2026 update might eventually shift those already pessimistic views even further.

Explore 4 other fair value estimates on Harmony Biosciences Holdings - why the stock might be worth over 5x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Harmony Biosciences Holdings research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Harmony Biosciences Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Harmony Biosciences Holdings' overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.